Toutes les photos(1)

Documents

G2295

Glimepiride

Name: Glimepiride
Brand: SIGMA

≥98% (HPLC), solid

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme

Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):

C₂₄H₃₄N₄O₅S

Numéro CAS:

93479-97-1

Poids moléculaire :

490.62

Numéro MDL:

MFCD00878417

Code UNSPSC :

12352200

ID de substance PubChem :

24895093

Nomenclature NACRES :

NA.77

Pureté

≥98% (HPLC)

Forme

solid

Couleur

white

Pf

212.2-214.5 °C

Solubilité

DMSO: >10 mg/mL

Auteur

Sanofi Aventis

Température de stockage

room temp

Chaîne SMILES

CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)C1=O

InChI

1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,16,19H,4-6,9-10,13-15H2,1-3H3,(H,25,31)(H2,26,27,30)/t16-,19-

Clé InChI

WIGIZIANZCJQQY-RUCARUNLSA-N

Informations sur le gène

human ... ABCC8(6833) , KCNJ1(3758) , KCNJ11(3767)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

Glimepiride is a class II biopharmaceutical second-generation sulfonylurea.

Application

Glimepiride has been used:

as a hypoglycemic drug to test its anti-diabetic functionality in human umbilical vein cells (HUVECs)
as a sulfonylurea ATP-sensitive potassium channel (K_ATP) channel inhibitor in breast cancer MDA-MB-231 cells
in glucose-stimulated insulin secretion (GSIS) assays of neonatal islet-like cell clusters (NICCs) to test its effect on insulin secretion

Glimepiride is currently used to treat type 2 diabetes.

Actions biochimiques/physiologiques

Glimepiride is a potent blocker of cardiac K_ATP channels activated by pinacidil with an IC₅₀ of 6.8 nM.

Glimepiride reduces blood glucose levels by stimulating the pancreatic β cells to secrete insulin hormone. It interacts with a 65-kD protein associated with β cells.

Caractéristiques et avantages

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictogrammes

GHS08

Mention d'avertissement

Warning

Mentions de danger

H361

Conseils de prudence

P201 - P202 - P280 - P308 + P313 - P405 - P501

Classification des risques

Repr. 2

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Équipement de protection individuelle

Eyeshields, Gloves, type N95 (US)

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Combination Therapy of Nifedipine and Sulphonylureas Exhibits a Mutual Antagonistic Effect on the Endothelial Cell Dysfunction Induced by Hyperglycemia Linked to Vascular Disease.

Li-Ping Wang et al.

Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 38(6), 2337-2347 (2016-05-21)

By inducing severe endothelial impairment, hypertension and diabetes are two leading causes of morbidity and mortality. Hypertensive patients with concomitant diabetes must take both antihypertensive and hypoglycaemic medications, for which there is a lack of experimental and clinical guidelines. This

A REVIEW ARTICLE ON GLIMEPERIDE: AN ORAL HYPOGLYCAEMIC DRUG

Tiwari A, et al.

International Journal of Advanced Research , 4, 920-927 (2016)

Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis.

W Rathmann et al.

Diabetes, obesity & metabolism, 15(1), 55-61 (2012-08-07)

To investigate therapy persistence, frequency of hypoglycaemia and macrovascular outcomes among type 2 diabetes patients with dipeptidyl peptidase-4 (DPP-4) inhibitors (DPP-4) and sulphonylureas (SU). Data from 19,184 DPP-4 (mean age: 64 years; 56% males) and 31,110 SU users (69 years;

Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.

Lan Gao et al.

International journal of technology assessment in health care, 28(4), 436-444 (2012-09-26)

The aim of this study was to evaluate the long-term cost-utility of liraglutide versus glimepiride as add-on therapy to metformin in patients with type 2 diabetes mellitus (T2DM), based on the results of clinical trial conducted in Asian population. The

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.

William T Cefalu et al.

Lancet (London, England), 382(9896), 941-950 (2013-07-16)

Sodium-glucose cotransporter 2 (SGLT2) inhibitors improve glycaemia in patients with type 2 diabetes by enhancing urinary glucose excretion. We compared the efficacy and safety of canagliflozin, an SGLT2 inhibitor, with glimepiride in patients with type 2 diabetes inadequately controlled with

Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique